Trial Profile
Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis +/- Asthma Sensitised to Phleum Pratense.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors Bial
- 13 Dec 2011 New trial record